VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
GenFleet Therapeutics Launches New Phase III Trial of GFH375 in KRAS G12D-Mutant NSCLC
GenFleet Therapeutics Launches New Phase III Trial of GFH375 in KRAS G12D-Mutant NSCLC
May 25, 2026 16:11 CST Updated May 26, 02:38
Share:
GenFleet Therapeutics
Innovative Drug Developer
